Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases.
The last earnings update was 14 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Fusion Antibodies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Fusion Antibodies's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fusion Antibodies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Fusion Antibodies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Fusion Antibodies's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Unable to compare Fusion Antibodies's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Unable to determine if Fusion Antibodies is high growth as no earnings estimate data is available.
Unable to determine if Fusion Antibodies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Fusion Antibodies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Fusion Antibodies's finances.
The net worth of a company is the difference between its assets and liabilities.
Fusion Antibodies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Fusion Antibodies's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Fusion Antibodies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 23.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Paul Gerard Kerr, Ph.D. has been Chief Executive Officer of Fusion Antibodies plc (also known as Fusion Antibodies Ltd.) since September 2011 and has been its Director since 2011. Dr. Kerr has been with Fusion Antibodies Ltd with over 10 years in a variety of technical roles, then 8 years in Business Development charged with developing the Contract Research services and seeking partners for the drug assets. Dr. Kerr has more than 20 years of Experience in Bioscience. He also serves as a Director of Fusion Antibodies Ltd.
Paul's compensation has increased whilst company is loss making.
Paul's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Fusion Antibodies management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO & Director
CFO, Company Secretary & Director
CTO & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Fusion Antibodies board of directors is about average.
Board of Directors
CEO & Director
CFO, Company Secretary & Director
CTO & Director
Senior Independent Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Fusion Antibodies individual insiders in the past 3 months, but not in substantial volumes.
What Type Of Shareholder Owns Fusion Antibodies plc's (LON:FAB)?
As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Fusion Antibodies is not a large company by global standards. … See our latest analysis for Fusion Antibodies AIM:FAB Ownership Summary, June 19th 2019 What Does The Institutional Ownership Tell Us About Fusion Antibodies? … We can see that Fusion Antibodies does have institutional investors; and they hold 33% of the stock.
Did You Manage To Avoid Fusion Antibodies's (LON:FAB) Painful 51% Share Price Drop?
Fusion Antibodies isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … In just one year Fusion Antibodies saw its revenue fall by 16%.
What Investors Should Know About Fusion Antibodies Plc's (LON:FAB) Financial Strength
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is FAB right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
Was Fusion Antibodies Plc's (LON:FAB) Earnings Decline Part Of A Broader Industry Downturn?
After looking at Fusion Antibodies Plc's (AIM:FAB) latest earnings update (31 March 2017), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … See our latest analysis for Fusion Antibodies How Well Did FAB Perform? … For Fusion Antibodies, its latest earnings (trailing twelve month) is UK£119.95K, which, in comparison to last year’s level, has plunged by a large -89.61%.
Fusion Antibodies Plc (LON:FAB): Can It Deliver A Superior ROE To The Industry?
View our latest analysis for Fusion Antibodies What you must know about ROE Return on Equity (ROE) weighs Fusion Antibodies’s profit against the level of its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Fusion Antibodies’s equity capital deployed. … Given a discrepancy of -1.27% between return and cost, this indicated that Fusion Antibodies may be paying more for its capital than what it’s generating in return.
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases. The company offers antibody identification and discovery services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of monoclonal antibodies. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and stable cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies worldwide. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.